Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TITAN phase II nivolumab-based tailored immunotherapy in advanced renal cell carcinoma
2016-002307-26Phase 2Completed
- Sponsor
- AIO-Studien
- Start
- Jun 2016
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of nivolumab and ipilimumab in renal cell carcinoma (RCC), sponsored by AIO-Studien. Primary endpoint: Objective response rate. Started Jun 2016; status: completed.
02
Drugs
nivolumabipilimumab
03
Conditions
renal cell carcinoma (RCC)
Beyond the preview
Go deeper on 2016-002307-26.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-002307-26.